Medtronic AT500 Brady/AT Stimulator Begins 260-Patient U.S. Trials
This article was originally published in The Gray Sheet
Medtronic's AT500 cardiac stimulator's first human implant marks the beginning of U.S. clinical trials for the device, following FDA approval of an investigational device exemption application in October.
You may also be interested in...
Lannett will launch a further seven products in fiscal 2021, after launching four products recently in the first quarter of FY21. The company also plans to pay off its Term Loan ‘A’ in full, by the end of November 2020.
Pfizer has now received a formal European Commission approval for its Nyvepria biosimilar pegfilgrastim. The approval puts the firm in direct competition with several other versions of the Neulasta original.
AstraZeneca's research head admits that the half dose approach was a lucky mistake – but one that could boost the vaccine's effectiveness and supplies. The US regulator may not be persuaded, however.